Abstract
Background: Monitoring the longevity of immunoglobulin G (IgG) responses following severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections is vital to understanding the role of antibodies in preventing infection.
Aims: To determine the quantitative IgG responses specific to the Spike-S1 (S1) receptor-binding domain (S1/RBD) region of the virus in serum samples taken between 4 weeks and 7 months after polymerase chain reaction (PCR) positivity in patients who are diagnosed with coronavirus disease-2019 (COVID-19).
Study design: A longitudinal study.
Methods: This study included 113 patients with a clinical and molecular diagnosis of COVID-19. The first and second serum samples were taken 1 and 7 months, respectively, after the PCR positivity. S1/RBD-specific IgG antibody response was assayed using anti-SARS-CoV- 2 QuantiVac ELISA (IgG) kit (Euroimmun, Lübeck, Germany). The neutralizing antibodies were investigated in 57 patients whose IgG test results were above the cut-off value.
Results: In 57 patients with SARS-CoV-2 IgG, the anti-SARS-CoV-2 IgG quantitative antibody levels significantly decreased after 7 months (Z = −2.197, p = 0.028). A correlation was detected between the anti-SARS-CoV-2 IgG and nAb percent inhibition (IH%) levels detected in 1 month (rs = 0.496, p < 0.001), but without significant correlation in serum samples taken on 7 months. The nAb IH% levels of the first and second were compared for COVID-19 severity and revealed no statistical difference ( p = 0.256). In the second serum sample, the nAb IH%s of patients with moderate COVID-19 showed a statistically significant difference from patients with mild COVID-19 ( p = 0.018), but without significant differences between severe and moderate or mild COVID-19.
Conclusion: SARS-CoV-2 quantitative IgG antibody titers are significantly reduced at long-term follow-up (> 6 months). Due to the limited information on seroconversion, comprehensive studies should be conducted for long-term follow-up of the immune response against SARS-CoV-2.
【초록키워드】 COVID-19, coronavirus disease, neutralizing antibody, SARS-CoV-2, IgG, coronavirus, immune response, Neutralizing antibodies, antibody, Infection, COVID-19 severity, severe acute respiratory syndrome coronavirus-2, severe acute respiratory syndrome Coronavirus, virus, ELISA, Moderate COVID-19, coronavirus disease-2019, polymerase chain reaction, serum, Immunoglobulin G, Seroconversion, IgG antibody, PCR, Molecular diagnosis, Immunoglobulin, longitudinal study, Germany, anti-SARS-CoV-2 IgG, response, Patient, Mild, monitoring, respiratory, Longevity, correlation, information, Euroimmun, Quantitative, moderate, SARS-CoV-2 IgG, Antibody titers, NAb, PCR positivity, Coronavirus-2, Long-term follow-up, IgG antibody titer, test results, IgG responses, Chain Reaction, IgG response, IgG test, acute respiratory syndrome, significant difference, acute respiratory syndrome coronavirus, significant differences, serum samples, domain, acute respiratory syndrome coronavirus-2, statistically significant difference, 113 patients, cut-off value, no statistical difference, serum sample, Lubeck, polymerase chain, significantly, investigated, diagnosed, conducted, reduced, determine, 113 patient, patients with moderate, patients with SARS-CoV-2, preventing infection, quantitative antibody level, 【제목키워드】 COVID-19, IgG, longitudinal, Level,